Kathryn Winter
Overview
Explore the profile of Kathryn Winter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
2933
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cabrit N, Cheugoua-Zanetsie M, Tierney J, Thirion P, Nankivell M, Winter K, et al.
Eur J Cancer
. 2025 Feb;
218:115292.
PMID: 39938127
Background: The use of surrogate endpoints may expedite the reporting of study outcomes of clinical trials. The validity of disease-free survival (DFS) as a surrogate for overall survival (OS) in...
2.
Kachnic L, Winter K, Suntharalingam M, Ilson D, Konski A, Lloyd S, et al.
Qual Life Res
. 2024 Jul;
33(10):2833-2844.
PMID: 39066879
Purpose/objectives: NRG/RTOG 0436 evaluated cetuximab added to chemoradiation (CRT) for non-operative esophageal cancer management. PRO objectives assessed improvement in the FACT-Esophageal cancer subscale (ECS), version 4, with cetuximab, and if...
3.
Sloan A, Winter K, Gilbert M, Aldape K, Choi S, Wen P, et al.
Neuro Oncol
. 2024 Jun;
26(9):1628-1637.
PMID: 38874333
Background: Immune checkpoint inhibitors (ICIs) have efficacy in several solid tumors but limited efficacy in glioblastoma (GBM). This study evaluated the safety of anti-CTLA-4 and anti-PD-1 ICIs alone or in...
4.
Faron M, Cheugoua-Zanetsie M, Tierney J, Thirion P, Nankivell M, Winter K, et al.
J Clin Oncol
. 2023 Jul;
41(28):4535-4547.
PMID: 37467395
Purpose: The optimal neoadjuvant treatment for resectable carcinoma of the thoracic esophagus (TE) or gastroesophageal junction (GEJ) remains a matter of debate. We performed an individual participant data (IPD) network...
5.
Safran H, Winter K, Ilson D, Wigle D, DiPetrillo T, Haddock M, et al.
Lancet Oncol
. 2022 Jan;
23(2):259-269.
PMID: 35038433
Background: Trastuzumab is a monoclonal antibody against HER2 (also known as ERBB2). The primary objective of the NRG Oncology/RTOG-1010 trial was to establish whether trastuzumab improves disease-free survival when combined...
6.
Siegel E, Ajidahun A, Berglund A, Guerrero W, Eschrich S, Putney R, et al.
PLoS One
. 2021 Dec;
16(12):e0260857.
PMID: 34882728
HPV infection results in changes in host gene methylation which, in turn, are thought to contribute to the neoplastic progression of HPV-associated cancers. The objective of this study was to...
7.
Faron M, Cheugoua-Zanetsie A, Thirion P, Nankivell M, Winter K, Cunningham D, et al.
Eur J Cancer
. 2021 Sep;
157:278-290.
PMID: 34555647
Introduction: Which neoadjuvant treatment for locally advanced thoracic oesophagus (TE) or gastro-oesophageal junction carcinoma is best remains an open question. Randomised controlled trials variously accrued patients with adenocarcinoma and squamous...
8.
Winter K, Pugh S
Urol Oncol
. 2019 Mar;
37(5):305-312.
PMID: 30926221
The purpose of this paper is to provide an introduction for investigators to many of the statistical considerations for clinical trials that will aid in their collaborations with statisticians for...
9.
Regine W, Winter K, Abrams R, Safran H, Kessel I, Chen Y, et al.
Adv Radiat Oncol
. 2018 Jun;
3(2):154-162.
PMID: 29904740
Purpose: NRG Oncology RTOG 9704 was the first adjuvant trial to validate the prognostic value of postresection CA19-9 levels for survival in patients with pancreatic carcinoma. The data resulting from...
10.
Suntharalingam M, Winter K, Ilson D
JAMA Oncol
. 2018 Mar;
4(6):888-889.
PMID: 29596545
No abstract available.